Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population


  • Filippo Rumi Alta Scuola di Economia e Management dei Sistemi Sanitari, Università Cattolica del Sacro Cuore, Roma - Italy
  • Michele Basile Alta Scuola di Economia e Management dei Sistemi Sanitari, Università Cattolica del Sacro Cuore, Roma - Italy
  • Americo Cicchetti Alta Scuola di Economia e Management dei Sistemi Sanitari, Università Cattolica del Sacro Cuore, Roma - Italy



Cost-Effectiveness Analysis , Economic evaluation, Influenza, Vaccines


Introduction. Influenza is a widespread acute respiratory disease and represents a serious Public Health problem, both from the NHS and society perspectives. The High Dose quadrivalent influenza vaccine (QIV HD) is a flu vaccine containing 4 times the antigens of a Standard Dose vaccine, resulting in demonstrated superior protection in the population aged 65 years and over.

Methods. The analysis has been conducted from the perspective of the NHS. The CEA focuses on the comparison between QIV HD and the QIV SD vaccine. The BIM aims to estimate the potential economic impact for the National Health Service (NHS) resulting from the use of QIV HD in clinical practice in subjects aged 65 or over, when considering its introduction in combination with currently used vaccines, QIV SD and adjuvanted TIV.

Results. In a scenario which considers hospitalizations possibly related to influenza, so including cardio-respiratory events, a dominant cost-effectiveness profile emerges in the comparison with QIV SD. In terms of budget impact, overall savings obtained by comparing the two scenarios regarding hospitalizations are equal to 92,766,429 € over the three years’ time horizon considered in the analysis.

Conclusions. Nowadays, also considering the state of emergency due to the spread of the SARS-CoV-2 virus, it is crucial to implement innovative health technologies that improve the efficiency and sustainability of the health system. Also, it is essential to protect the elderly population, helping to avoid overload and healthcare systems disruption due to the many COVID-19 hospitalizations.


Download data is not yet available.


Zhou B, Wentworth DE. Influenza A virus molecular virology techniques. Methods Mol Biol. 2012;865:175-192. PMID:22528160 DOI:

Bertolani A, Fattore G, Pregliasco F. The hospitalization burden of influenza: just the tip of the iceberg? Global & Regional Health Technology Assessment. 2018;1-9. DOI:

Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292(11):1333-1340. DOI:

Hollingsworth R, Palmu A, Pepin S, et al. Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: rationale and design of a real-world pragmatic randomized clinical trial. Am Heart J. 2021;237:54-61. PMID:33722585 DOI:

DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635-645. PMID:25119609 DOI:

Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose versus standard-dose influenza vaccination for older adults: a systematic review and meta-analysis. Expert Rev Vaccines. 2018;17(5):435-443. PMID:29715054 DOI:

Istituto Nazionale di Statistica – disponibile su:; Popolazione residente al 1° gennaio; (ultimo accesso aprile 2021)

Dati coperture vaccinali. Ministero della Salute. Online; (ultimo accesso aprile 2021)

Somes MP, Turner RM, Dwyer LJ, Newall AT. Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: A systematic review and meta-analysis. Vaccine. 2018;36(23):3199-3207. PMID:29716771 DOI:

Trucchi C, Paganino C, Orsi A, et al. Hospital and economic burden of influenza-like illness and lower respiratory tract infection in adults ≥50 years-old. BMC Health Serv Res. 2019;19(1):585. PMID:31426795 DOI:

Capri S, Barbieri M, de Waure C, Boccalini S, Panatto D. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population. Hum Vaccin Immunother. 2018;14(6):1331-1341. PMID:29425079 DOI:

Rosano A, Bella A, Gesualdo F, et al. Investigating the impact of influenza on excess mortality in all ages in Italy during recent seasons (2013/14-2016/17 seasons). Int J Infect Dis. 2019;88:127-134. PMID:31401203 DOI:

Colamesta V, Tamburrano A, Barbara A, et al. Cost-consequence analysis of influenza vaccination among the staff of a large teaching hospital in Rome, Italy: A pilot study. PLoS One. 2019;14(11):e0225326. PMID:31725788 DOI:

Pitrelli A. Introduction of a quadrivalent influenza vaccine in Italy: a budget impact analysis. J Prev Med Hyg. 2016;57(1):E34-E40. PMID:27346938

Dal Negro RW, Turco P, Povero M. Cost of influenza and influenza-like syndromes (I-LSs) in Italy: results of a cross-sectional telephone survey on a representative sample of general population. Respir Med. 2018;141:144-149. DOI:

Safety and immunogenicity of High-Dose Quadrivalent Influenza vaccine in Participants ≥65 years in the US. -. Identifier NCT03282240, Online; (ultimo accesso marzo 2021)

Chit A, Roiz J, Aballea S. An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model. PLoS One. 2015;10(7):e0133606. PMID:26222538 DOI:

Scalone L, Cortesi PA, Ciampichini R, Cesana G, Mantovani LG. Health related quality of life norm data of the general population in Italy: results using the EQ-5D-3L and EQ-5D-5L instruments. EBPH 2015;12(3):e11457-1- e11457-15; disponibile su:; (ultimo accesso giugno 2021)

Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess. 2003;7(35):1-170. PMID: 14609480. DOI:

Istituto Superiore di Sanità (ISS) – Epicentro – Online; L’epidemiologia per la sanità pubblica – Influenza; (ultimo accesso marzo 2021)

Chit A, Becker DL, DiazGranados CA, Maschio M, Yau E, Drummond M. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial. Lancet Infect Dis. 2015;15(12):1459-1466. PMID:26362172 DOI:

van Aalst R, Russo EM, Neupane N, et al. Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population: estimating the impact on hospitalization cost for cardio-respiratory disease. Vaccine. 2019;37(32):4499-4503. PMID:31262590 DOI:

23. WHO Guide on standardization of economic evaluations of immunization programmes. 2019. Online:; (ultimo accesso aprile 2021)



How to Cite

Rumi, F., Basile, M., & Cicchetti, A. (2021). Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population. Global and Regional Health Technology Assessment, 8(1), 105–113.



Original Research Articles


Received 2021-02-20
Accepted 2021-07-06
Published 2021-08-04


Most read articles by the same author(s)

1 2 > >>